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Most environmental carcinogens, including those in tobacco 6 To whom correspondence should be addressed at Department of Preventive smoke, require metabolic activation by cytochromes P450
Medicine, University of Southern California, School of Medicine, Los Angeles, CA 90033, USA to exert deleterious effects. Genetic polymorphisms in these enzymes may provide a genetic basis for interThe well described genetic polymorphism of the CYP2D6 individual variability in susceptibility to environmental lung gene influences response to a wide variety of therapeutic carcinogens. A genetic polymorphism is well established for agents metabolized by the CYP2D6 enzyme product.
the P450 dependent mono-oxygenase, CYP2D6 (debrisoquine CYP2D6 also appears to play a role, along with other 4-hydroxylase) (1) . CYP2D6 plays a role in the metabolism cytochrome P450 enzymes, in the metabolic activation of of the tobacco specific nitrosamine 4-(methylnitrosamino)-1-the tobacco specific nitrosamine, NNK, as well as meta-(3-pyridyl)-1-butanone (NNK*) (2) as well as nicotine (3).
bolism of nicotine to cotinine. While impaired activity of
Recently, Kato et al. (4) demonstrated that levels of DNA CYP2D6 was strongly protective against lung cancer in nitrosamine adducts are reduced in subjects who carry two some studies, primarily based on phenotyping, the literature inactivating alleles of the CYP2D6 gene. Thus, it is plausible is conflicting. The molecular basis of CYP2D6 deficiency that persons with genetically determined reduction in CYP2D6 is now well understood, enabling the use of genotyping to activity may have a lower risk of lung cancer. classify individuals. We therefore examined whether lung
The possible association between the polymorphism of cancer risk is reduced by the presence of four CYP2D6 CYP2D6 and lung cancer risk has been investigated in alleles associated with impaired activity due to an inactivatseveral studies. Initially, the CYP2D6 polymorphism was ing mutation-CYP2D6*4, CYP2D6*3, CYP2D6*5 and classified by phenotyping with either debrisoquine, sparteine CYP2D6*16-among 341 incident cases of lung cancer and or dextromethorphan. The method distinguishes extensive 710 population controls of Caucasian or African-American metabolizers (EM) from poor metabolizers (PM). Ayesh and ethnicity in Los Angeles County, California. We did not colleagues (5) first suggested that extensive metabolizers are confirm a strong association between the presence of at markedly increased risk of lung cancer, a result confirmed these inactivating alleles and lung cancer risk [odds ratio
by Caporaso et al. (6) and Law et al. (7), but not others (OR) ϭ 0.90, 95% confidence interval (CI) 0.60-1.35 for (8-13). Caporaso et al. (14) suggested that the association Caucasians], although there was a small decreased risk may be particularly high in subjects with occupational among the African-Americans (OR ⍧ 0.66, 95% CI 0.38-exposure to polyaromatic hydrocarbons and asbestos; no 1.14). Among smokers, when the data are stratified accordother studies of CYP2D6 have examined this hypothesis. ing to lifetime smoking history, there is a suggestion of an Recently, Bouchardy (15) reported an association between association limited to Caucasian smokers of <35 pack-CYP2D6 phenotype and lung cancer risk limited to heavy years, the median for all smokers in these data (OR smokers. Interpretation of studies of phenotype is hampered ⍧ 0.49, 95% CI 0.23-1.04). However, among Africanby the possibility that disease status, or the resulting cachexia American smokers, who smoke less than Caucasians, the and/or medication use, may alter the measured phenotype. association did not differ between smoking categories. We
The enumeration of inactivating mutations in the CYP2D6 also examined the possible role of additional copies of the has enabled the identification of the vast majority of phenotypic CYP2D6 gene, which lead to enhanced CYP2D6 activity, poor metabolizers by genotyping of peripheral blood DNA in increasing lung cancer risk. Among controls the preval- (16) (17) (18) . However, studies of the CYP2D6 genotype in relation ence of having more than two copies of the CYP2D6 gene to lung cancer risk also give mixed results (19-24). and no inactivating alleles was 4.3% for Caucasians and Some persons have more than two copies of the CYP2D6 4.9% for African-Americans. Relative to subjects with an gene, without any inactivating mutations, resulting in markedly inactivating allele, those with an additional copy of the increased enzyme activity (25) and possibly an increased risk of liver cancer (26). There are no published data on CYP2D6 
CYP2D6D
) (28) . We also examined subjects without any of we also adjusted for smoking by including continuous terms for the natural these inactivating alleles for additional copies of the CYP2D6 logarithm of pack-years and a product term for the natural logarithm of packgene to test the hypothesis that additional copies increase the years and years since quitting smoking as previously described (30) . Adjusted risk of lung cancer.
and unadjusted estimates differed only slightly. Whenever the expected number of cases or controls with a given genotype was Ͻ5, we present unadjusted exact odds ratios and confidence intervals (31) . All P values presented are
Subjects and methods
two-sided. The protocol was reviewed and approved by the human subjects committee Eligibility criteria for the study were as follows: resident in Los Angeles at the University of Southern California. We obtained written informed consent County, aged 40-84, able to complete a questionnaire in English, Caucasian from all subjects. (non-Hispanic) or African-American ethnicity, and no prior cancer other than non-melanoma skin cancer. We enrolled all subjects between January 1, 1991, Laboratory methods and May 1, 1994.
DNA was prepared either from buffy coats (isolated from 10 whole blood) Incident cases of lung cancer were identified from 35 hospitals in Los or directly from 10 ml whole blood. In either case, the blood was collected Angeles County selected to provide approximately equal numbers of Africanin an EDTA tube and frozen in Los Angeles and stored at -80°C prior to American and Caucasian lung cancer patients. Cases were diagnosed between shipment on dry ice to Newcastle upon Tyne, United Kingdom for processing. September 1, 1990 , and January 6, 1994. At the time of ascertainment, cases
The samples were thawed and a nuclear fraction was prepared by lysis with had to be within 7 months of diagnosis. Enrolment was limited to newly 10 volumes 0.32 M sucrose, 10 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1% diagnosed cases to avoid bias that could result from the selective enrolment Triton X-100 and centrifugation at 1600 g for 5 min. The pellet was of those who had survived for a long period in the event that CYP2D6 resuspended in 2 ml phosphate buffered saline and DNA was extracted on an genotype were related to lung cancer prognosis.
Applied Biosystems model 340A nucleic acid extractor using the recomControls under age 65 years were sampled from among persons listed with mended protocol. the Department of Motor Vehicles (DMV) and those aged 65 and over were a random selection of Medicare beneficiaries provided by the Health Care CYP2D6 genotyping Financing Administration (HCFA). To try to achieve an approximate balance The CYP2D6*3 and CYP2D6*4 alleles were detected by a single tube PCR of age (within 10-year intervals), ethnicity and gender between cases and method described previously (32) . Where subjects were positive for both the controls, we sampled potential controls based on the distributions of these CYP2D6*3 and CYP2D6*4 alleles, an additional allele specific PCR assay factors among cases diagnosed in Los Angeles County during the 3 years that amplified the CYP2D6*3 allele only, followed by digestion with BstNI prior to the start of enrolment.
to determine whether this allele was also positive for the G1934A mutation We identified 859 potentially eligible cases. Of these, 207 had died by the of the CYP2D6*4 allele was also performed. RFLP analysis with XbaI was time physicians received our request for permission to contact them. The also carried out as described previously to detect the CYP2D6*5 and physicians declined permission for us to contact 36 of the 652 patients not CYP2D6*16 alleles and alleles represented by bands of 44 kb and 15 ϩ 9 kb known to be ineligible. Among the remaining 616, we were unable to locate and 11 kb (33) . This XbaI analysis did not resolve the known heterogeneity 92, 158 declined to participate and we ended the study before we could enrol in the 44 kb region and, therefore, for all subjects who did not test positive 10 cases who agreed to participate. Thus, we enrolled 356 eligible cases-167 for any of the four alleles associated with reduced activity (*3, *4, *5 or *16) African-American and 189 Caucasians.
we performed RFLP analysis with EcoRI to distinguish between bands of 44 We sent letters to 3193 potential controls asking them to write their phone and 42 kb. In addition to invariant bands of 15, 9.5 and 9.0 kb, subjects number on an enclosed postcard and return it. We sent up to four letters if positive for the 44 kb XbaI band had an additional band of 14 kb with EcoRI, we received no response. We looked up phone numbers of all non-respondents whereas those positive for the 42 kb band had an additional band of 12.5 kb. and tried 12 times to call each subject with a listed phone number. We then
The 44 kb band with XbaI (14 kb with EcoRI) arises as a result of an attempted to visit the addresses of all subjects not reached after 12 tries as additional copy of the pseudogene CYP2D7 and is therefore not expected to well as all unlisted subjects. affect CYP2D6 activity, but the 42 kb band (12.5 kb with EcoRI) represents The address was incorrect for 752 subjects and we were unable to obtain two copies of the CYP2D6 gene in tandem on the same chromosome and is a usable address for these. We determined that 157 persons to whom we sent expected to result in higher enzyme activity. letters were not eligible because they no longer lived in Los Angeles County.
For 343 cases and 716 controls, we had adequate DNA to test for the Of the 2284 subjects with valid addresses we obtained a response on 1573.
presence of the CYP2D6*4 allele, the most common mutant allele in these Responses for these 1573 indicated that 94 were ineligible, 71 were deceased, population groups on 343 cases and 716 controls. For all but two controls, 351 declined to participate and 1057 expressed willingness to participate.
there was also sufficient DNA to test for the CYP2D6*3 allele. For 336 cases Among these 1057 subjects, 46 could not be reached before the end of the and 708 controls, there was sufficient DNA to perform the XbaI RFLP analysis study, 831 were eligible on screening and 180 were ineligible. We were unable to detect the CYP2D6*5 and CYP2D6*16 alleles and, where relevant, the to enrol 100 of the 831 eligible and willing subjects before we terminated data collection. Because the DMV tape does not contain race identifiers and EcoR1 RFLP analysis. Genotype was assigned based on all available data. Results lung cancer risk was slightly stronger among AfricanAmericans (OR ϭ 0.66, 95% CI 0.38-1.14) than among Table I includes distributions of sex, age, smoking history, and Caucasians (OR ϭ 0.90, 95% CI 0.60-1.35), but this difference lung cancer histology by case-control status and Africanwas not statistically significant (P ϭ 0.36 for the difference American or Caucasian ethnicity. Age was very evenly in odds ratios). For this reason, as well for comparison with balanced; there was a slight deficit of female controls. As the study of Caporaso et al. (6), we present odds ratios for all expected, cases had markedly greater smoking history than subjects combined as well as separately by race. Not surpriscontrols (Table I ) .
ingly, given the rarity of lung cancer cases among non-smokers, The frequency (f) of all inactivating alleles combined (*3, the odds ratios for the presence of an activating mutation in *4, *5 and *16) was lower (P ϭ 0.0009) among Africanrelation to lung cancer risk was not appreciably altered when American (f ϭ 0.148) than among Caucasian controls (f ϭ the analysis was restricted to smokers (Table II) . 0.222) (Table II) . Among African-Americans the frequencies It has been suggested that the role of the CYP2D6 polymorphof the inactivating alleles were 0.073 for the CYP2D6*4 allele, ism in relation to lung cancer risk may vary according to 0.069 for the CYP2D6*5 allele and 0.006 for the CYP2D6*3 quantitative smoking history (15,34). However, few studies allele. Among Caucasians, the allele frequencies were 0.181 have tested this hypothesis. We therefore examined the associfor CYP2D6*4, 0.029 for CYP2D6*5 allele and 0.012 for ation between CYP2D6 genotype and lung cancer risk separ-CYP2D6*3. The only subject positive for the CYP2D6*16 ately in two categories of lifetime smoking history divided at allele was a Caucasian case.
35 pack-years, the median for smokers in the study as a whole CYP2D6 genotype did not differ significantly by gender or (Table III) . Among Caucasians, we observed a decreased risk age (data not shown). Because CYP2D6 is one of the enzymes of lung cancer among subjects with at least one inactivating involved in metabolism of nicotine to cotinine it has been allele limited to the lighter smokers (OR ϭ 0.49, 95% CI hypothesized that poor metabolizers of debrisoquine may be 0.23-1.04, P for difference in odds ratios between smoking smoking averse (3). However, in these data, CYP2D6 genotype strata ϭ 0.031). Among African-American smokers, who in was not related to smoking, assessed by various indicesthese data and others consume fewer cigarettes than Caucasian pack-years, years smoked, maximum amount smoked, usual smokers, the odds ratio did not differ by smoking category (P amount smoked-in either ethnic group (data not shown).
for difference ϭ 0.354). Using 40 pack-years as the cut-point We examined the hypothesis that genotypes resulting in instead gave virtually the same result (data not shown). A test impaired CYP2D6 activity decrease the risk of lung cancer of interaction using genotype multiplied by a continuous term (Table II) . The risk of lung cancer did not vary appreciably for pack-years is not dependent on the choice of cut-points. between subjects with one versus two inactivating alleles. For
The slopes for the continuous pack-years did not differ by this reason, as well as to enable comparison with previous genotype for African-Americans (P ϭ 0.684). For Caucasians reports (6,14), we present odds ratios for subjects with one or the P value for the difference in the slopes for smoking in two inactivating alleles together, as well as separately. For relation to lung cancer by genotype was 0.132, giving weak both Caucasians and African-Americans, we observed a slight support to the finding of a difference in odds ratios by smoking and non-statistically significantly decreased risk of lung cancer status in the categorical analysis. for subjects with at least one inactivating allele. The association between the presence of at least one inactivating allele and Although stratification by histology, particularly within race, leads to sparse data, the presence of at least one inactivating Johannson et al. (25) have reported that some subjects have amplification of the CYP2D6 gene resulting in increased may be more strongly associated with adenocarcinoma (OR ϭ 0.67, 95% CI 0.42-1.08 for all subjects combined) than with CYP2D6 activity relative to subjects with only two functional copies of the gene. It is reasonable to postulate that persons squamous and small cell carcinomas (OR 0.97, 95% 0.62-1.52) (Table IV) . For comparability with previous studies, we with an additional copy of the CYP2D6 gene and no inactivating alleles would be at increased risk of lung cancer relative to also calculated the associations between the presence of an inactivating allele and all lung cancer other than adenosubjects with inactivating alleles. However, previous studies of lung cancer have not included data on additional copies of carcinoma. The OR for the presence of at least one allele associated with an inactivation mutation was 1.02 (95% CI the CYP2D6 gene. Therefore, we characterized subjects with no inactivation mutations according to whether they had only 0.64-1.61) for whites; 0.81 (95% CI 0.43-1.53) for AfricanAmericans and 0.89 (95% CI ϭ 0.62-1.29) for the two ethnic two or more than two functional copies of the CYP2D6 gene and compared their risk of lung cancer to subjects with an groups combined (data not shown).
Caporaso et al. (14) reported that the association between inactivating allele (Table VI) . The proportion of controls with Ͼ2 copies of the CYP2D6 gene without an inactivating CYP2D6 activity and lung cancer risk may be particularly strong among persons with occupational exposure to asbestos mutation was low and comparable for Caucasians (4.4%) and African-Americans (4.9%) (Table VI) . Only one subject (a and polyaromatic hydrocarbons. Therefore, we examined possible modification of the association between CYP2D6 genoCaucasian control) had more than three copies of the CYP2D6 gene without an inactivating mutation. Compared with subjects type and lung cancer risk by occupational exposure to these agents (Table V) . We found no evidence that asbestos exposure with at least one inactivating allele, subjects with Ͼ2 copies of the CYP2D6 gene and no inactivating alleles were at slightly and CYP2D6 genotype interact in relation to lung cancer risk. Likewise the data do not support an interaction with PAH and non-statistically significantly increased risk of lung cancer for both African-Americans (OR ϭ 1.41, 95% CI 0.46-4.34) exposure-an odds ratio for lung cancer of 0.38 for the presence of two inactivating alleles limited to Caucasians with and Caucasians (OR ϭ 1.85, 95% CI 0.68-5.02). However, the risk increased with the number of functional copies of the occupational exposure was based on only one exposed case and is far from statistically significant (95% CI 0.02-2.18).
CYP2D6 gene only for Caucasians ( (Table VII) . In our data, the and occupation.
Although the frequency of all inactivating alleles combined presence of at least one inactivating allele may be more strongly associated with risk of adenocarcinoma (Table IV) , is significantly lower in African-Americans than Caucasians, there was no major association with lung cancer risk within although, as in all previous studies, sample sizes do not produce reliable estimates of associations by cell type. Indeed, either ethnic group. Persons with at least one inactivating allele were at slightly, but non-statistically significantly decreased risk a greater association with adenocarcinoma is plausible given the activity of CYP2D6 in NNK metabolism and the hypothesis of lung cancer among African-Americans (OR ϭ 0.66, 95% CI 0.38-1.14). While our study was somewhat limited in power that NNK may be more important in the etiology of adenocarcinoma than of squamous cell carcinoma (36) . Over the past to precisely quantify weak associations of this magnitude, we had sufficient numbers to have confirmed the much stronger 40 years, alterations in commercial cigarettes in developed countries, largely related to the use of filter tips, to decrease associations (OR ϭ 0.2 or less) observed in three studies of phenotyping (5-7). Thus, the failure to confirm this strong tar and nicotine yields have substantially increased delivery of NNK and other nitrosamines to the smoker (36) . In tandem, association is informative.
The literature on the CYP2D6 polymorphism and lung the incidence of adenocarcinoma of the lung has risen markedly, more dramatically than rates of squamous cell carcinoma cancer risk is somewhat inconsistent (Table VII) . Because data were not presented separately for the intermediate metabolizer (36, 37) . While it has been suggested that differences in the association category in all publications, we tabulated the only effect estimate that can be produced for all studies-the crude odds between the CYP2D6 polymorphism and lung cancer risk between studies may be due to different smoking profiles ratio for poor metabolizers (or their genotype equivalent) relative to all other subjects. However, due to the low frequency between study populations (15,24,34) this hypothesis is hard to evaluate because smoking-stratified results have been preof poor metabolizers, the power for this comparison is limited. Among the nine phenotyping studies, three studies show a sented in only three previous studies (11,15,24). Indeed, in several studies of either genotype or phenotype the quantitative marked decreased risk of lung cancer (odds ratio of 0.2 or lower) (5-7) which was statistically significant in all but the smoking history is not known for both cases and controls (12, 13, (19) (20) (21) (22) (23) Agundez et al. (22) reverse-a slightly stronger association among the lightest smokers, as we also observed in the entire study population Homozygotes for inactivating alleles were also decreased risk of lung cancer, but to a lesser degree in the studies of Wolf (Table III) . On further examination, the apparent interaction between smoking and CYP2D6 in relation to lung cancer risk et al. association between CYP2D6 activity and smoking among Only two other studies have presented analyses of the CYP2D6 polymorphism in relation to lung cancer risk stratified their control subjects-there is a higher than expected number of light smokers among subjects with high CYP2D6 activity by smoking history (11,24). The data of Stucker et al. (24) are consistent with ours in finding that the presence of at least (30 versus 23 expected, overall P value for association ϭ 0.06). Although McCracken et al. (3) had predicted that high one inactivating allele is associated with lung cancer risk only among lighter smokers, classified in that study as less than 30 CYP2D6 activity might actually cause one to smoke more, because of rapid metabolism of nicotine, our data and that of pack-years (OR ϭ 0.39, 95% CI 0.22-0.65). Shaw et al. (11) found no pattern consistent with interaction between smoking other others do not support an association between the CYP2D6 polymorphism and smoking behaviour (38, 39) . Furthermore, and CYP2D6 activity in relation to lung cancer. Thus, the literature give little support to the hypothesis that the CYP2D6 the CYP2D6-smoking interaction in relation to lung cancer risk presented by Bouchardy et al. (15) reflects an implausible polymorphism is related to lung cancer risk only among very heavy smokers. Further data would be needed to evaluate the protective effect of smoking in relation to lung cancer among subjects in the lower two-thirds of CYP2D6 activity combined suggestion in our data that the CYP2D6 polymorphism might actually be more strongly related to lung cancer risk among with a five-fold increased risk limited to the upper tertile of smoking. A smoking-lung cancer association limited to the lighter smokers. While this pattern may reflect chance variation alone, it is conceivable that at very high levels of exposure, third of the population with highest CYP2D6 activity is simply not consistent with the repeated observation of very strong genetic variation in ability to metabolize a particular carcinogen substrate could be largely irrelevant. associations between smoking and lung cancer in four decades of studies with no data on CYP2D6 activity. This examination It is worth considering the possibility that study results may differ because of the wide range of control populations among of the data of Bouchardy et al. (15) highlights the perils of overinterpreting data on interaction from studies that are too studies, ranging from hospitals controls with COPD or cancer to volunteers from laboratory staff or blood banks. Ours is the small to support such an analysis, as has been discussed recently (40) .
first published study to use general population controls. While * Odds ratio (OR) and 95% confidence interval (CI) are adjusted for age, sex and smoking. Where expected cell counts are Ͻ5, unadjusted odds ratios and confidence intervals were calculated using exact methods. Subjects without an allele associated with decreased CYP2D6 activity (including those with and without gene amplification) serve as the reference group. Cases of each cell type are compared with all controls.
in most previous studies response rates were not given, the to previous studies, we attempted to estimate potential control selection bias. We sent a very brief questionnaire to a random response rate among healthy population controls is typically lower than among hospital patients (41) particularly true when sample of 201 individuals who had not responded to invitations to enrol. We received the questionnaire back from 66 people a blood sample is required. As expected, response rates were somewhat low in our population. One factor may have been (33%) and also obtained the questionnaire information from an additional 55 when knocking on doors of non-respondents. that our target population included a high proportion of residents of low income areas in whom participate rates are
The prevalence of ever having smoked was very similar among these non-respondents (61%) compared with the study subjects known to be lower (42) . Nonetheless, our study subjects are likely to be more representative of the target population than (66%). Furthermore, current smoking among controls was similar to that observed among persons of comparable age and either laboratory staff or blood bank donors who represent only a small percentage (5-10%) of that portion of the general ethnicity in a contemporary national survey (44) . Thus, we feel reassured that our controls are representative of the population (57-70%) eligible to give blood (43) . In contrast * Totals add to less in previous tables due to missing occupational data on two cases and three controls. ** The following work was considered to be associated with likely asbestos exposure: employment in insulation work or repair of heating/cooling systems, shipyard work, new construction work prior to 1975, boiler-making, coke-oven work. Possible exposure included employment in floor installation, roofing, welding, smelting, foundry, engine repair, rubber work, building renovation, truck driving. Workers with no history of employment in any of these jobs were classified as unlikely exposure. †Odds ratio (OR) and 95% confidence interval (CI) are adjusted for age, sex and smoking. Where expected cell counts are Ͻ5, unadjusted odds ratios and confidence intervals were calculated using exact methods. The reference group are subjects with at least one inactivating mutation.
population that gave rise to the lung cancer cases particularly reasons for hospital admission among persons with chronic illnesses. However, the associations in the positive studies (of with regard to this critical risk factor for lung cancer.
Comparing the phenotyping studies (Table VII) , the both genotype and phenotype) are driven primarily by the very low proportion of poor metabolizers among the cases (2% prevalence of the poor metabolizer phenotype among controls is higher in the studies showing the strongest associations, or less). Given this observation, it is justifiable to speculate that if the with a maximum of 13% among the hospital controls in the study of Caporaso et al. (6) It is conceivable that poor CYP2D6 polymorphism is related to prognosis, an association identified for the genetic polymorphism of CYP1A1 and lung metabolizers are over-represented among some series of hospitalized patients because this phenotype may cause a higher cancer (46) , differences among studies in the proportion of poor metabolizers among cases might be due to selection of incidence of adverse drug reactions (45) , common underlying * Odds ratio (OR) and 95% confidence interval (CI) are adjusted for age, sex and smoking. Where expected cell counts are less than 5, unadjusted odds ratios and confidence intervals were calculated using exact methods. The reference group are subjects with 0 or 1 functions/copies and at least one inactivating mutation. † Cases of each cell type are compared with all controls. Only two cases with 'other' histologies had Ͼ2 copies of the CYP2D6 gene without inactivating mutations and thus separate odd ratios for this histology category are not presented.
cases with more or less favourable prognosis among studies. tion in Los Angeles County suggesting that the cases we enrolled were representative of those occurring during the study We identified incident cases from a wide network of hospitals and the distribution of cell types reflected the overall distribuperiod. However in studies of phenotyping, the requirement that subjects must not have had previous chemotherapy or radiation inactivating alleles which together account for over 90% of phenotypic poor metabolizers, we did not assess all alleles may favour enrolment of subjects with favourable prognosis such as, surgical candidates who will be over-represented associated with decreased activity. Because of the discovery of the CYP2D6*6A allele (T allele) during the conduct of the among hospital patients. This hypothesis could be evaluated by examining the survival profiles of cases from previous study (48), we examined a random sample of controls and observed only two heterozygotes out of 86 Caucasians giving studies, but cannot be evaluated from the published data and so it remains speculative. While many medications can interfere an allele frequency of only 0.01 and observed no subjects with this allele among 36 African-American controls. It is clear with determination of phenotype, most appear to slow metabolism and thus should not produce a spuriously very low that failure to measure an allele with such a low frequency (or other rare alleles) will not account for more than a trivial proportion of poor metabolizers among the cases.
It can be argued that studies of genotyping will not reveal amount of misclassification in this study and simply cannot obscure odds ratios for poor metabolizers in the range of 0.2 the associations seen in studies of phenotyping because all rare alleles associated with decreased activity were not measured in observed in the positive studies of phenotype. Furthermore, because the associations in these studies are driven by the all genotyping studies. While we assayed for the four
